MA-VERACODE
23.8.2022 14:21:12 CEST | Business Wire | Press release
Veracode , a leading global provider of application security testing solutions, today released data revealing that the financial services industry ranks among the best for overall flaw percentage when compared to other industries, but has one of the lowest fix rates for software security flaws. The sector also falls to the middle of the pack for high-severity flaws, with 18 percent of applications containing a serious vulnerability, suggesting financial firms should prioritize identifying and remediating the flaws that matter most.
The findings were outlined in the company’s annual State of Software Security report v12, which analyzed 20 million scans across half a million applications in the financial, technology, manufacturing, retail, healthcare and government sectors. Across the six industries, the financial sector has the second-lowest proportion of applications containing security flaws, at 73 percent. In last year’s report, the industry boasted the lowest number of software security flaws across all sectors but has been overtaken by manufacturing in this year’s study. Despite having fewer flaws overall, the financial services sector comes joint last with technology and government for the lowest proportion of flaws that are fixed.
“One of the advantages of serving the software development community for so many years is that Veracode can see changes in development practices across industries over time. We found that while financial services applications have fewer security flaws than last year, the sector lags behind other industries when it comes to fix rate. Our research showed that security training can significantly improve remediation speeds, and that companies whose development teams had completed hands-on training using real-life applications fixed flaws 35 percent faster than those without such training,” said Chris Eng, Chief Research Officer at Veracode.
Securing the Global Software Supply Chain
While there is undoubtedly still room for progress in terms of both flaw prevalence and remediation rates, when financial services organizations do fix vulnerabilities, they move at a quicker pace than most.
Eng said, “The U.S. Executive Order on Cybersecurity, alongside mandates on security controls regarding open-source usage, such as GDPR and the New York Department of Financial Services Cybersecurity Regulations, has highlighted the importance of securing the software supply chain. Being a highly regulated sector may go some way to explain the financial industry’s relative speed in addressing vulnerable libraries discovered through software composition analysis (SCA).”
Flaws in third-party libraries found through SCA tend to stick around longer for all industries, with 30 percent still unresolved after two years. When it comes to addressing open-source vulnerabilities, however, the finance sector remediates at the same pace as other industries for the first year but then quickens its pace to gain a month on the cross-industry average.
Although the finance sector outperforms most other industries in fix times for flaws discovered by dynamic, SCA, and static, the study found there is still ample room for continued improvement when looking at the number of days it takes to resolve 50 percent of flaws—116 days for dynamic analysis, 385 days for SCA, and 288 days for static analysis. With third-party components comprising as much as 90 percent* of an application’s codebase, scanning early and often using a combination of testing types reduces unplanned emergency remediation work and mitigates the risk of introducing third-party security flaws into software.
The Veracode State of Software Security v12 financial services snapshot is available to download here and a video of the findings is available to watch here .
* The Linux Foundation Statista, Joseph Perlow, “A Summary of Census II: Open Source Software Application Libraries the World Depends On”: https://www.statista.com/statistics/617136/digital-population-worldwide/ , March 7, 2022
About the State of Software Security Report
The Veracode State of Software Security (SoSS) v12 analyzed the full historical data from Veracode services and customers. This accounts for a total of more than half a million applications (592,720) that used all scan types, more than a million dynamic analysis scans (1,034,855), more than five million static analysis scans (5,137,882) and more than 18 million software composition analysis scans (18,473,203). All those scans produced 42 million raw static findings, 3.5 million raw dynamic findings, and six million raw SCA findings.
The data represents large and small companies, commercial software suppliers, software outsourcers, and open-source projects. In most analyses, an application was counted only once, even if it was submitted multiple times as vulnerabilities were remediated, and new versions uploaded.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com , on the Veracode blog and on Twitter .
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005500/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
